FDA advisors signaled some preference for Moderna’s two-shot COVID-19 vaccine schedule in the youngest Americans over Pfizer’s three-shot series. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
